KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Revenue (2016 - 2025)

Novavax has reported Revenue over the past 16 years, most recently at $147.1 million for Q4 2025.

  • Quarterly results put Revenue at $147.1 million for Q4 2025, up 66.61% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 55.28% YoY), and the annual figure for FY2025 was $1.1 billion, up 64.69%.
  • Revenue for Q4 2025 was $147.1 million at Novavax, up from $70.4 million in the prior quarter.
  • Over the last five years, Revenue for NVAX hit a ceiling of $734.6 million in Q3 2022 and a floor of $70.4 million in Q3 2025.
  • Median Revenue over the past 5 years was $204.6 million (2021), compared with a mean of $292.7 million.
  • Biggest five-year swings in Revenue: skyrocketed 13143.38% in 2021 and later plummeted 88.5% in 2023.
  • Novavax's Revenue stood at $222.2 million in 2021, then surged by 60.85% to $357.4 million in 2022, then dropped by 18.48% to $291.3 million in 2023, then crashed by 69.69% to $88.3 million in 2024, then soared by 66.61% to $147.1 million in 2025.
  • The last three reported values for Revenue were $147.1 million (Q4 2025), $70.4 million (Q3 2025), and $175.0 million (Q2 2025) per Business Quant data.